{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:51Z","timestamp":1794048831442,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["676129"],"award-info":[{"award-number":["676129"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["676129"],"award-info":[{"award-number":["676129"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["676129"],"award-info":[{"award-number":["676129"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["676129"],"award-info":[{"award-number":["676129"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["676129"],"award-info":[{"award-number":["676129"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["676129"],"award-info":[{"award-number":["676129"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hellenic Institute for the Study of Sepsis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clarithromycin may act as immune-regulating treatment in sepsis and acute respiratory dysfunction syndrome. However, clinical evidence remains inconclusive. We aimed to evaluate whether clarithromycin improves 28-day mortality among patients with sepsis, respiratory and multiple organ dysfunction syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a multicenter, randomized, clinical trial in patients with sepsis. Participants with ratio of partial oxygen pressure to fraction of inspired oxygen less than 200 and more than 3 SOFA points from systems other than the respiratory function were enrolled between December 2017 and September 2019. Patients were randomized to receive 1 gr of clarithromycin or placebo intravenously once daily for 4 consecutive days. The primary endpoint was 28-day all-cause mortality. Secondary outcomes were 90-day mortality; sepsis response (defined as at least 25% decrease in SOFA score by day 7); sepsis recurrence; and differences in peripheral blood cell populations and leukocyte transcriptomics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-five patients were allocated to each arm. By day 28, 27 (49.1%) patients in the clarithromycin and 25 (45.5%) in the placebo group died (risk difference 3.6% [95% confidence interval (CI) \u2212\u200915.7 to 22.7]; <jats:italic>P<\/jats:italic>\u2009=\u20090.703, adjusted OR 1.03 [95%CI 0.35\u20133.06]; <jats:italic>P<\/jats:italic>\u2009=\u20090.959). There were no statistical differences in 90-day mortality and sepsis response. Clarithromycin was associated with lower incidence of sepsis recurrence (OR 0.21 [95%CI 0.06\u20130.68]; <jats:italic>P<\/jats:italic>\u2009=\u20090.012); significant increase in monocyte HLA-DR expression; expansion of non-classical monocytes; and upregulation of genes involved in cholesterol homeostasis. Serious and non-serious adverse events were equally distributed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Clarithromycin did not reduce mortality among patients with sepsis with respiratory and multiple organ dysfunction. Clarithromycin was associated with lower sepsis recurrence, possibly through a mechanism of immune restoration.<\/jats:p>\n                <jats:p><jats:italic>Clinical trial registration<\/jats:italic> clinicaltrials.gov identifier <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345992\">NCT03345992<\/jats:ext-link> registered 17 November 2017; EudraCT 2017-001056-55.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-022-04055-4","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T18:02:38Z","timestamp":1655575358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Eleni","family":"Karakike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon P.","family":"Scicluna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roumpoutsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Mitrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karampela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Karageorgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Psaroulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achillefs","family":"Pitsoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Chaloulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene T.","family":"Schrijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantzeska","family":"Frantzeskaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvina","family":"Lada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"De Bels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Floros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzana","family":"Anisoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Antoniadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Patrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glykeria","family":"Vlachogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Mouloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Antoniadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joost","family":"Wiersinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraklis","family":"Tsangaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"key":"4055_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","volume":"46","author":"C Fleischmann-Struzek","year":"2020","unstructured":"Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46:1552\u201362.","journal-title":"Intensive Care Med"},{"key":"4055_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study. Lancet. 2020;395:200\u201311.","journal-title":"Lancet"},{"key":"4055_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jama.2017.17687","volume":"319","author":"HC Prescott","year":"2018","unstructured":"Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA. 2018;319:62\u201375.","journal-title":"JAMA"},{"key":"4055_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJMoa1500896","volume":"372","author":"PR Mouncey","year":"2015","unstructured":"Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372:1301\u201311.","journal-title":"N Engl J Med"},{"key":"4055_CR5","doi-asserted-by":"crossref","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330\u20131341.","DOI":"10.1001\/jama.2020.17023"},{"key":"4055_CR6","first-page":"CD002243","volume":"12","author":"D Annane","year":"2019","unstructured":"Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y, et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev. 2019;12:CD002243.","journal-title":"Cochrane Database Syst Rev."},{"key":"4055_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","volume":"47","author":"RS Hotchkiss","year":"2019","unstructured":"Hotchkiss RS, Colston E, Yende S, Angus DC, Moldawer LL, Crouser ED, et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit Care Med. 2019;47:632\u201342.","journal-title":"Crit Care Med"},{"key":"4055_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44:275\u201381.","journal-title":"Crit Care Med"},{"key":"4055_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1164\/rccm.201204-0645OC","volume":"186","author":"J Leentjens","year":"2012","unstructured":"Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012;186:838\u201345.","journal-title":"Am J Respir Crit Care Med"},{"key":"4055_CR10","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1097\/CCM.0000000000001090","volume":"43","author":"JL Vincent","year":"2015","unstructured":"Vincent JL, Marshall JC, Dellinger RP, Simonson SG, Guntupalli K, Levy MM, et al. Talactoferrin in severe sepsis: results from the phase ii\/iii oral talactoferrin in severe sepsis trial. Crit Care Med. 2015;43:1832\u20138.","journal-title":"Crit Care Med"},{"key":"4055_CR11","doi-asserted-by":"publisher","first-page":"e98960","DOI":"10.1172\/jci.insight.98960","volume":"3","author":"B Francois","year":"2018","unstructured":"Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3:e98960.","journal-title":"JCI Insight"},{"key":"4055_CR12","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","volume":"54","author":"T Van der Poll","year":"2021","unstructured":"Van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity. 2021;54:2450\u201364.","journal-title":"Immunity"},{"key":"4055_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2213-2600(20)30080-1","volume":"8","author":"TDY Reijnders","year":"2020","unstructured":"Reijnders TDY, Saris A, Schultz MJ, van der Poll T. Immunomodulation by macrolides: therapeutic potential for critical care. Lancet Respir Med. 2020;8:619\u201330.","journal-title":"Lancet Respir Med"},{"key":"4055_CR14","first-page":"CD009764","volume":"10","author":"SC Herath","year":"2018","unstructured":"Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;10:CD009764.","journal-title":"Cochrane Database Syst Rev."},{"key":"4055_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12845","author":"KZ Vardakas","year":"2017","unstructured":"Vardakas KZ, Trigkidis KK, Apiranthiti KN, Falagas ME. The dilemma of monotherapy or combination therapy in community-acquired pneumonia. Eur J Clin Invest. 2017. https:\/\/doi.org\/10.1111\/eci.12845.","journal-title":"Eur J Clin Invest."},{"key":"4055_CR16","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia\u2014an official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200:e45\u201367.","journal-title":"Am J Respir Crit Care Med."},{"key":"4055_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/jac\/dkt475","volume":"69","author":"EJ Giamarellos-Bourboulis","year":"2014","unstructured":"Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, Tsangaris I, Koutelidakis I, Marioli A, et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother. 2014;69:1111\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"4055_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1086\/529439","volume":"46","author":"EJ Giamarellos-Bourboulis","year":"2008","unstructured":"Giamarellos-Bourboulis EJ, Pech\u00e8re JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46:1157\u201364.","journal-title":"Clin Infect Dis"},{"key":"4055_CR19","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1128\/AAC.02974-15","volume":"60","author":"T Tsaganos","year":"2016","unstructured":"Tsaganos T, Raftogiannis M, Pratikaki M, Christodoulou S, Kotanidou A, Papadomichelakis E, et al. Clarithromycin leads to long-term survival and cost benefit in ventilator-associated pneumonia and sepsis. Antimicrob Agents Chemother. 2016;60:3640\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"4055_CR20","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1128\/AAC.05798-11","volume":"56","author":"A Spyridaki","year":"2012","unstructured":"Spyridaki A, Raftogiannis M, Antonopoulou A, Tsaganos T, Routsi C, Baziaka F, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother. 2012;56:3819\u201325.","journal-title":"Antimicrob Agents Chemother"},{"key":"4055_CR21","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","volume":"174","author":"N Garin","year":"2014","unstructured":"Garin N, Genn\u00e9 D, Carballo S, Chuard C, Eich G, Hugli O, et al. \u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894\u2013901.","journal-title":"JAMA Intern Med"},{"key":"4055_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13054-020-2830-x","volume":"24","author":"GP Leijte","year":"2020","unstructured":"Leijte GP, Rimmel\u00e9 T, Kox M, Bruse N, Monard C, Gossez M, et al. Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes. Crit Care. 2020;24:110.","journal-title":"Crit Care"},{"key":"4055_CR23","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","volume":"45","author":"RS Hotchkiss","year":"2019","unstructured":"Hotchkiss RS, Colston E, Yende S, Crouser ED, Martin GS, Albertson T, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45:1360\u201371.","journal-title":"Intensive Care Med"},{"key":"4055_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","volume":"180","author":"C Meisel","year":"2009","unstructured":"Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180:640\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"4055_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13073-021-00948-1","volume":"13","author":"X Brands","year":"2021","unstructured":"Brands X, Haak BW, Klarenbeek AM, Butler J, Uhel F, Qin W, et al. An epigenetic and transcriptomic signature of immune tolerance in human monocytes through multi-omics integration. Genome Med. 2021;13:131.","journal-title":"Genome Med"},{"key":"4055_CR26","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00134-009-1609-y","volume":"35","author":"S Barlage","year":"2009","unstructured":"Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Gl\u00fcck T, et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med. 2009;35:1877\u201385.","journal-title":"Intensive Care Med"},{"key":"4055_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","volume":"24","author":"RJ Arts","year":"2016","unstructured":"Arts RJ, Novakovic B, Ter Horst R, Carvalho A, Bekkering S, Lachmandas E, et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 2016;24:807\u201319.","journal-title":"Cell Metab"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04055-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T10:46:36Z","timestamp":1660560396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04055-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4055"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04055-4","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the declaration of Helsinki and national and institutional standards. The protocol and informed consent form were approved in Greece [National Organization for Medicines (51239\/01-06-2017), National Ethics Committee (52086\/2017)] and Belgium [Federal Agency of Medicines and Health Products (1078386\/16-04-2018), Central Ethics Committee, Erasme University Hospital (P2018\/376, 19-10-2018)]. Study registration was with EudraCT (2017-001056-55) and Clinicaltrials.gov (NCT03345992). Written informed consent was provided by patients or legal representatives, prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E. Karakike is supported by the Horizon2020 Marie Sk\u0142odowska-Curie International Training Network \u201cthe European Sepsis Academy\u201d (grant number 676129- granted to the National and Kapodistrian University of Athens). I.T. Schrijver is supported by the Horizon2020 Marie Sk\u0142odowska-Curie International Training Network \u201cthe European Sepsis Academy\u201d (grant number 676129- granted to Lausanne University Hospital) and received a scholarship from the Soci\u00e9t\u00e9 Acad\u00e9mique Vaudoise (Lausanne, Switzerland). N. Dauby is a post-doctorate clinical master specialist of the Belgian F.R.S-FNRS and reports personal fees from Roche and Boehringer Ingelheim, and non-financial support from Pfizer, Janssen and Merck Sharp & Dohme, all outside the submitted work. T. Roger is funded by the European Union Horizon 2020 Marie Sk\u0142odowska-Curie Action Innovative Training Network European Sepsis Academy (ESA-ITN, grant number 676129) and by the European Union Horizon 2020 grant ImmunoSep (847422). W. J. Wiersinga is supported by the Netherlands Organization for Scientific Research (VIDI grant 91716475) and the Horizon2020 Marie Sk\u0142odowska-Curie International Training Network \u201cthe European Sepsis Academy\u201d and received consulting fee paid to the host institution from MDS, GSK and Swedish Orphan Biovitrum AB. A. Antoniadou has received honoraria from Gilead, Pfizer, MSD, ViiV, BMS, Astellas and independent educational grants from Gilead, GSK and Biotest. D. Grimaldi received consultation fees from Transgene SA Illkirch-Graffenstaden (France). E. J. Giamarellos-Bourboulis has received honoraria from Abbott CH, bioM\u00e9rieux, GSK, InflaRx GmbH, ThermoFisher Brahms GmbH, Sobi and XBiotech Inc; independent educational grants from Abbott CH, AxisShield, bioM\u00e9rieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, Sobi and XBiotech Inc.; and funding from the Horizon2020 Marie Sk\u0142odowska-Curie International Training Network \u201cthe European Sepsis Academy\u201d (granted to the National and Kapodistrian University of Athens); the Horizon 2020 European Grants ImmunoSep and RISC in COVID (granted to the Hellenic Institute for the Study of Sepsis); and the Horizon Health grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not report any conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}